Templeton questions AsiaPharmÆs financial results

Templeton, a minority shareholder of AsiaPharm, is opposing a S$357.4 million management buyout offer for the Chinese pharmaceutical company and says the latest fourth quarter results are crucial in assessing the offer.


Quick Poll

How will you alter your portfolio after the US election result?





« View results

Previous polls ››

Underweight US
  16%
 
Overweight US
  42%
 
Underweight EMs
  7%
 
Raise cash levels
  20%
 
No change
  14%
TOTAL VOTES: 146
Comment on this

« Back

Previous polls ››

December 2016/January 2017 Magazine
AsianInvestor Magazine